Benitec Biopharma Ltd (BNTC)

[georgejjl]

29 April 2015
BENITEC’S SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT PRESENTS AT AUSTRALIAN GENE THERAPY CONFERENCE
Sydney, Australia: Benitec Biopharma is pleased to advise that Dr David Suhy, Benitec’s SVP Research & Development, will present an overview and update of Benitec’s lead clinical program, TT-034, at the Australian Gene and Cell Therapy Society’s 9th Biennial Conference in Melbourne today. The title of his presentation is “TT-034: A ddRNAi-based vector used for the treatment of individuals infected with the hepatitis C virus.”
Benitec is pleased to be a sponsor of this meeting, which is being held at the University of Melbourne today and tomorrow. Other speakers include Benitec’s collaborator at 4D Molecular Therapeutics, Professor David Schaffer, Benitec’s collaborator at the University of New South Wales, Professor Maria Kavallaris, Professor Mark Kay from Stanford University, and Benitec’s CEO, Dr Peter French.
Dr Suhy’s presentation is attached as it contains previously un-presented data. Ends
For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

http://blt.live.hqi.com.au/IRM/Company/ShowPage.aspx/PDFs/1540-10000000/BENITECPRESENTSATAGCTSCONFERENCE

Good luck and GOD bless,

George